| Breast
Cancer Research Small Molecules |
|
|
| Target |
Products |
| ALK |
A-83-01, SB
216763 |
| mTOR |
Torin 1, Torin
2 |
| AURKB |
ZM
447439, TC-A 2317 |
| CTNNB1 |
XAV 939, iCRT
14, xSTAx-VHLL |
| BRAF |
SB 590885, CG 858 |
| MET |
PHA 665752 |
| HSP90 |
VER 155008 |
| MDM2 |
SP 141, Nutlin
3a |
| SRC |
A 419259, ND1-YL2 |
| Wnt |
PKF 115584
(Calphostin C), FH 535 |
| MYC |
KJ Pyr 9 |
| CDK4/6 |
BSJ-03-204, Ribociclib,
BSJ-04-132 |
| RAR |
BMS 753 |
| PIK3CB |
LY 294002
hydrochloride, Wortmannin |
| MEK1 |
SL 327 |
| FOXM1 |
RCM 1 |
| BRD4 |
(+)-JQ1, MZ 1 |
| STAT3 |
Stattic, NSC
74859, HJC 0416 |
| ESR1 |
ICI
182,780, G-1 |
| FOXA1 |
(+)-JQ1 |
| PARP |
SK
575, Olaparib |
| Bcl-xL |
A 1331852 |
| ErbB2/HER2 |
Tucatinib |
| LMTK3 |
C28 |
|
|
|
|
| Colorectal Cancer Research Small Molecules |
|
|
| Target |
Products |
| ALK |
A 83-01, SB 431542,
Ceritinib, TL 13-112 |
| ATM |
KU 55933, VE
821, AZ 5704 |
| AXL |
XL 184 |
| BRAF |
SB 590885, SJF
0628, CG 858 |
| EGFR |
Gefinitib-based
PROTAC® 3, Iressa,
Erlotinib, EMI 48 |
| ERBB2 |
Neratinib, SJF
1528, Tucatinib |
| HGF/MET |
SU
5416, Crizotinib, SJF 8240 |
| HIPPO |
Verteporfin, XMU
MP 1, (R)-PFI 2 |
| IGFR |
Ceritinib, 6bK,
Linsitinib |
| JAK |
PKF
115584 (Calphostin C), FH 535 |
| KRAS |
LC 2, MRTX 849 |
| MAPK |
SB 202190, PD
0325901, SB 706504, SJFα |
| mTOR |
Rapamycin, Torin
1 |
| MYC |
KJ Pyr
9, 10058-F4 |
| NOTCH |
DAPT, Compound
E, TCH-165, DBZ |
| RET |
SU 5416, SPP
86, Vandetanib, Selpercatinib |
| SMARCA4 |
SGC SMARCA-BRDVIII,
FHT 1015, FHT 2344 |
| SRC |
Bosutinib, A
419259 |
| VEGF/R |
SU 5402, SU
5416, Cediranib, Vandetanib |
| WNT |
CHIR 99021, IWP
2, Wnt-C59, LP 922056, FH 535, WIKI4 |
| YAP |
Verteporfin |
|
|
|
|
| Liver Cancer Research Small Molecules |
|
|
| Target |
Products |
| ATM |
KU 55933, VE
821, AZ 5704 |
| BRAF |
SB
590885, Sorafenib, CG 858, SJF 0628 |
| CTNNB1 |
XAV 939, WIC1,
endo-IWR 1, xStAx-VHLL |
| FGFR |
SU 5402, PD
173074, Cediranib, Nintedanib |
| FLT4 |
XL 184 |
| FXR |
GW 4064, GW
3965 |
| IDH1 |
AGI 5198 |
| KRAS |
LC 2, MRTX
849, AMG 510 |
| MET |
SU
5416, Crizotinib, SJF 8240 |
| PDGFR |
Sunitinib, CP
673451, Imatinib, Sorafenib, JNJ 10198409, Cediranib,
Linifanib |
| PI3K |
LY
294002, Wortmannin, Omipalisib, PI 3065 |
| RET |
SU 5416, SPP
86, Vandetanib, Selpercatinib |
| VEGFR |
Cediranib, Vandetanib,
Linifanib |
| WNT |
CHIR 99021, IWP
2, Wnt-C59, LP 922056,WIKI4, WIC1, PT-65 |
|
|
|
|
| Lung Cancer Research Small Molecules |
|
|
| Target |
Products |
| KRAS |
LC 2, BAY 293,
MRTX 849 |
| EGFR |
Erlotinib, EMI
48 |
| AKT |
AT 7867 |
| ROS1 |
SB 590885 |
| SMARCA4,
SMARCA2 |
SGC SMARCA-BRDVIII |
| ERBB4 |
Neratinib |
| STAT3 |
A 419259 |
| JAK1 |
PKF 115584, FH
535 |
| MYC |
KJ Pyr 9 |
| mTOR |
Torin 1, Torin
2 |
| NOTCH |
DBZ (also
available as Ancillary Material Grade) |
| PTEN |
SL 327 |
| RET |
SPP 86, Vandetanib |
| ALK |
Crizotinib |
| BRAF |
SJF 0628,
Vemurafenib |
| MET |
SJF 8240, XL
184 |
| BCL2 |
ABT 263, A
1331852 |
| WEE1 |
Adavosertib |
|
|
|
|
| Pancreatic Cancer Research Small Molecules |
|
|
| Target |
Products |
| KRAS |
LC 2, BAY 293,
MRTX 849 |
| EGFR |
Erlotinib, EMI 48 |
| AKT |
AT 7867 |
| VTPase |
SB 590885 |
| SMARCA4,
SMARCA2 |
SGC SMARCA-BRDVIII,
FHT 1015, FHT 2344 |
| ERBB4 |
Neratinib |
| STAT3 |
A 419259 |
| JAK1 |
PKF 115584, FH
535 |
| MYC |
KJ Pyr 9 |
| mTOR |
Torin1, Torin
2 |
| NOTCH |
DBZ |
| PTEN |
SL 327 |
| Wee1 |
Adavosertib |
|
|
|
|
| Prostate Cancer Research Small Molecules |
|
|
| Target |
Products |
| AKT1 |
Akti-1/2, SC
79, AT 7867 |
| AR |
Cl-4AS-1, GSK
650394, ARCC 4 (PROTAC®) |
| AURKA |
Lestaurtinib, Anacardic
acid |
| CTNNB1 |
endo-IWR 1, XAV 939, FzM1.8 |
| CYP17A1 |
Abiraterone acetate |
| ERG |
ERGi-USU |
| EZH2 |
3-Deazaneplanocin A
hydrochloride, UNC 1999, JQEZ5 |
| NR3C1 |
Gap
27, Hydrocortisone, Alsterpaullone |
| GSK-3B |
CHIR 99021, SB
216763 |
| HSPA5 |
Pifithrin-μ, VER 155008 |
| MYC |
10058-F4, KJ
Pyr 9 |
| NCOA1 |
Lys-CoA |
| PIK3CA/PIK3CB |
LY 294002
hydrochloride, Wortmannin, Omipalisib |
| TMPRSS2 |
Nafamostat mesylate |
| FOXM1 |
RCM 1 |
| BRD4 |
MZ 1, (+)-JQ1,
AT 1 (PROTAC®) |
| CUL3 |
WS 383 |
| BMI1 |
PRT 4165 |
| Asah1 |
Oleylethanolamide |
| FOXA1 |
(+)-JQ1 |
| NR2F2 |
CIA 1 |
| SPOP |
SPOP-i-6lc |